The National Institute for Health and Clinical Excellence (NICE) has
issued a Technology Appraisal for the use of pemetrexed for the
treatment of malignant pleural mesothelioma, and makes the following
recommendations (taken directly from source):

* Pemetrexed is recommended as a treatment option for malignant
pleural mesothelioma only in people who have a World Health
Organisation (WHO) performance status of 0 or 1, who are considered to
have advanced disease and for whom surgical resection is considered
inappropriate
* Patients currently receiving pemetrexed who do not fall into the
patient population defined above should have the option to continue
therapy until they and their clinicians consider it appropriate to
stop.

http://asbestosmesotheliomalawyer.blogspot.com/